Stifel last night downgraded Mirati Therapeutics (MRTX) to Hold from Buy with a price target of $59, down from $83. The firm expects the announced takeover by Bristol Myers (BMY) to close without issue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics downgraded to Hold from Buy at Stifel
- Mirati Therapeutics reports Q3 EPS ($2.49), consensus ($2.83)
- Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mirati Therapeutics receives MHRA approval for KRAZATI